logo_abgenomics

About the Company

AbGenomics (private) is a biopharmaceutical company developing antibody therapeutics for inflammatory diseases and cancer. The Company’s lead candidate is AbGn-168H (neihulizumab), a targeted therapy for the treatment of acute graft-vs-host disease (aGvHD). AbGn-168H is currently being evaluated in a Phase Ib trial in steroid refractory aGvHD, with results expected in the second half of 2016. Results from a proof-of-concept Phase II trial in psoriatic arthritis (PsA) demonstrated that 40% of subjects treated with AbGn-168H achieved a 20% reduction in symptoms at week 12. The Company’s preclinical oncology product candidates are next generation antibody drug conjugates (ADC) for solid tumors.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research